Phone: 1.510.856.5600|info@anthera.com

Press Releases

 
Press Releases
  Date Title and Summary View
Aug 14, 2017
HAYWARD, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society Clinical Trial Network (ECFS CTN) Executive Committee. The aim of the ECF...
Aug 9, 2017
HAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN).  Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be e...
Aug 9, 2017
RESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and EuropeRESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development NetworkBRIGHT, Phase 2 study of blisibimod in IgA Nephropathy remains on track to report topline data in Q3Executed equity purchase agreement for the sale of up to $10 million in c...
Jul 10, 2017
HAYWARD, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN) Protocol Review Committee. The CFF T...
Jul 6, 2017
Study is being conducted in the US, Europe, and IsraelTop line data expected end of 2017 or early 2018 HAYWARD, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Anthera (Nasdaq:ANTH) today announced that it has commenced screening in Europe in the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency (EPI) due to cystic fibros...
May 15, 2017
Four-week non-inferiority, Coefficient of Fat Absorption (CFA) primary endpoint comparing Sollpura to Pancreaze in patients with exocrine pancreatic insufficiency due to cystic fibrosisStudy design leverages input from the US FDA and CF CommunityTarget enrollment of 150 patients 7 years of age and olderTop line data expected end of 2017 or early 20...
May 10, 2017
RESULT, pivotal Phase 3 Study of Sollpura, is expected to screen the first patient in MayFavorable trends on weight, height, and body mass index ("BMI") from the Extension Period of the SOLUTION Study of SollpuraCompletion of dosing in the Phase 2 BRIGHT-SC Study of blisbimod in patients with IgA NephropathyClosing of initial $15 million public off...
Apr 28, 2017
HAYWARD, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) announced today that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-8 reverse stock split of its common stock, effective as of April 28, 2017 at 5:00 p.m. Eastern Time.  A Certificate ...
Apr 10, 2017
HAYWARD, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals. (Nasdaq:ANTH) today announced the completion of dosing in the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in patients with IgA nephropathy (IgAN).  After Week 24, patients were given the opportunity to continue blinded treatment fo...
Mar 29, 2017
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the findings from the Extension Period of the Phase 3 SOLUTION, non-inferior...
Page:
1
... NextLast
= add release to Briefcase
Print Friendly